percutaneous coronary stenting

DEVICE2 trials

Sponsors

Medtronic Vascular, Ya-Wei Xu

Conditions

Coronary Artery DiseaseSTEMI - ST Elevation Myocardial Infarction

Unknown Phase

The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial

CompletedNCT00217256

Medtronic VascularCoronary Artery Disease

Start: 2004-02-29End: 2010-12-31Updated: 2011-06-27

Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.

Ya-Wei XuSTEMI - ST Elevation Myocardial Infarction

Start: 2022-04-01End: 2023-04-30Target: 120Updated: 2022-05-26

Related Papers

Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).

2011-05-0167 citations

Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).

2009-12-0134 citations